|
G |
Ada |
adenosine deaminase |
increases activity |
ISO |
ammonium acetate results in increased activity of ADA protein |
CTD |
PMID:19900420 |
|
NCBI chr 2:163,565,703...163,592,154
Ensembl chr 2:163,568,504...163,592,159
|
|
G |
Adra1a |
adrenergic receptor, alpha 1a |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ADRA1A mRNA |
CTD |
PMID:33404927 |
|
NCBI chr14:66,872,705...67,009,549
Ensembl chr14:66,872,700...67,008,617
|
|
G |
Ampd2 |
adenosine monophosphate deaminase 2 |
increases activity |
ISO |
ammonium acetate results in increased activity of AMPD2 protein |
CTD |
PMID:19900420 |
|
NCBI chr 3:107,981,375...107,993,982
Ensembl chr 3:107,981,378...107,993,967
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases activity |
ISO |
ammonium acetate results in increased activity of AMPD3 protein |
CTD |
PMID:19900420 |
|
NCBI chr 7:110,367,291...110,411,612
Ensembl chr 7:110,367,413...110,411,612
|
|
G |
Asl |
argininosuccinate lyase |
increases activity |
ISO |
ammonium acetate results in increased activity of ASL protein |
CTD |
PMID:16009439 |
|
NCBI chr 5:130,040,099...130,053,222
Ensembl chr 5:130,040,099...130,058,088
|
|
G |
Ass1 |
argininosuccinate synthetase 1 |
increases activity |
ISO |
ammonium acetate results in increased activity of ASS1 protein |
CTD |
PMID:16009439 |
|
NCBI chr 2:31,360,282...31,410,682
Ensembl chr 2:31,360,219...31,410,684
|
|
G |
Atp1a1 |
ATPase, Na+/K+ transporting, alpha 1 polypeptide |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP1A1 protein |
CTD |
PMID:33404927 |
|
NCBI chr 3:101,483,535...101,512,023
Ensembl chr 3:101,483,535...101,512,000
|
|
G |
Atp1a2 |
ATPase, Na+/K+ transporting, alpha 2 polypeptide |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP1A2 protein |
CTD |
PMID:33404927 |
|
NCBI chr 1:172,099,276...172,125,631
Ensembl chr 1:172,099,276...172,125,631
|
|
G |
Atp1a3 |
ATPase, Na+/K+ transporting, alpha 3 polypeptide |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP1A3 protein |
CTD |
PMID:33404927 |
|
NCBI chr 7:24,677,592...24,705,338
Ensembl chr 7:24,677,592...24,705,383
|
|
G |
Atp2a2 |
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP2A2 protein |
CTD |
PMID:33404927 |
|
NCBI chr 5:122,591,576...122,640,288
Ensembl chr 5:122,591,576...122,640,288
|
|
G |
Atp2b2 |
ATPase, Ca++ transporting, plasma membrane 2 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP2B2 protein |
CTD |
PMID:33404927 |
|
NCBI chr 6:113,720,803...114,019,574
Ensembl chr 6:113,720,792...114,019,574
|
|
G |
Atp2b3 |
ATPase, Ca++ transporting, plasma membrane 3 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP2B3 protein |
CTD |
PMID:33404927 |
|
NCBI chr X:72,546,356...72,632,267
Ensembl chr X:72,546,692...72,614,611
|
|
G |
Atp2b4 |
ATPase, Ca++ transporting, plasma membrane 4 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ATP2B4 protein |
CTD |
PMID:33404927 |
|
NCBI chr 1:133,630,416...133,728,755
Ensembl chr 1:133,627,195...133,728,779
|
|
G |
Calr |
calreticulin |
increases expression decreases expression |
ISO |
ammonium acetate results in increased expression of CALR protein ammonium acetate results in decreased expression of CALR mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 8:85,568,717...85,573,560
Ensembl chr 8:85,568,479...85,573,563
|
|
G |
Cat |
catalase |
increases activity decreases activity multiple interactions |
ISO |
ammonium acetate results in increased activity of CAT protein ammonium acetate results in decreased activity of CAT protein Dizocilpine Maleate inhibits the reaction [ammonium acetate results in decreased activity of CAT protein] |
CTD |
PMID:12885441 PMID:15945352 |
|
NCBI chr 2:103,284,249...103,315,498
Ensembl chr 2:103,284,194...103,315,505
|
|
G |
Cd74 |
CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated) |
increases expression |
ISO |
ammonium acetate results in increased expression of CD74 mRNA; ammonium acetate results in increased expression of CD74 protein |
CTD |
PMID:33404927 |
|
NCBI chr18:60,936,921...60,945,724
Ensembl chr18:60,936,920...60,945,724
|
|
G |
Cd8a |
CD8 subunit alpha |
increases expression |
ISO |
ammonium acetate results in increased expression of CD8A mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 6:71,350,411...71,356,155
Ensembl chr 6:71,350,411...71,356,157
|
|
G |
Chrne |
cholinergic receptor, nicotinic, epsilon polypeptide |
increases expression |
ISO |
ammonium acetate results in increased expression of CHRNE mRNA |
CTD |
PMID:33404927 |
|
NCBI chr11:70,505,709...70,510,074
Ensembl chr11:70,505,709...70,510,042
|
|
G |
Cldn10 |
claudin 10 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of CLDN10 mRNA; ammonium acetate results in decreased expression of CLDN10 protein |
CTD |
PMID:33404927 |
|
NCBI chr14:119,025,283...119,111,937
Ensembl chr14:119,025,320...119,112,901
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
ISO |
ammonium acetate results in increased expression of CRHR2 mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 6:55,067,033...55,110,001
Ensembl chr 6:55,067,034...55,110,001
|
|
G |
Gpr83 |
G protein-coupled receptor 83 |
increases expression |
ISO |
ammonium acetate results in increased expression of GPR83 mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 9:14,771,038...14,782,085
Ensembl chr 9:14,771,506...14,782,085
|
|
G |
Gria4 |
glutamate receptor, ionotropic, AMPA4 (alpha 4) |
decreases expression |
ISO |
ammonium acetate results in decreased expression of GRIA4 mRNA; ammonium acetate results in decreased expression of GRIA4 protein |
CTD |
PMID:33404927 |
|
NCBI chr 9:4,417,893...4,796,250
Ensembl chr 9:4,417,896...4,796,234
|
|
G |
Grin2a |
glutamate receptor, ionotropic, NMDA2A (epsilon 1) |
multiple interactions decreases expression |
ISO |
Allopurinol inhibits the reaction [ammonium acetate results in decreased expression of GRIN2A protein] |
CTD |
PMID:20084674 |
|
NCBI chr16:9,385,765...9,813,744
Ensembl chr16:9,385,762...9,813,424
|
|
G |
Grin2b |
glutamate receptor, ionotropic, NMDA2B (epsilon 2) |
decreases expression |
ISO |
ammonium acetate results in decreased expression of GRIN2B protein |
CTD |
PMID:20084674 |
|
NCBI chr 6:135,690,219...136,150,658
Ensembl chr 6:135,690,231...136,150,509
|
|
G |
Grm6 |
glutamate receptor, metabotropic 6 |
increases expression |
ISO |
ammonium acetate results in increased expression of GRM6 mRNA |
CTD |
PMID:33404927 |
|
NCBI chr11:50,741,205...50,757,035
Ensembl chr11:50,741,512...50,757,035
|
|
G |
H2-T23 |
histocompatibility 2, T region locus 23 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of RT1-A2 mRNA |
CTD |
PMID:33404927 |
|
NCBI chr17:36,340,869...36,343,593
Ensembl chr17:36,340,665...36,343,747
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
ammonium acetate results in increased expression of HMOX1 protein |
CTD |
PMID:12420312 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
ammonium acetate results in increased expression of ICAM1 mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
[Ibuprofen co-treated with Eucalyptol] inhibits the reaction [ammonium acetate results in increased expression of IL1B mRNA]; Eucalyptol inhibits the reaction [ammonium acetate results in increased expression of IL1B mRNA]; Ibuprofen inhibits the reaction [ammonium acetate results in increased expression of IL1B mRNA] |
CTD |
PMID:36346500 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
ammonium acetate results in increased expression of IL6 mRNA [Ibuprofen co-treated with Eucalyptol] inhibits the reaction [ammonium acetate results in increased expression of IL6 mRNA]; Eucalyptol inhibits the reaction [ammonium acetate results in increased expression of IL6 mRNA]; Ibuprofen inhibits the reaction [ammonium acetate results in increased expression of IL6 mRNA] |
CTD |
PMID:36346500 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor 1 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of ITPR1 |
CTD |
PMID:33404927 |
|
NCBI chr 6:108,190,044...108,528,077
Ensembl chr 6:108,190,057...108,528,070
|
|
G |
Lhb |
luteinizing hormone beta |
increases expression |
ISO |
ammonium acetate results in increased expression of LHB mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 7:45,070,370...45,071,278
Ensembl chr 7:45,070,244...45,071,321
|
|
G |
Mag |
myelin-associated glycoprotein |
increases expression |
ISO |
ammonium acetate results in increased expression of MAG mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 7:30,598,600...30,614,347
Ensembl chr 7:30,598,601...30,614,298
|
|
G |
Maoa |
monoamine oxidase A |
increases activity multiple interactions |
ISO |
ammonium acetate results in increased activity of MAOA protein Dizocilpine Maleate inhibits the reaction [ammonium acetate results in increased activity of MAOA protein] |
CTD |
PMID:12885441 |
|
NCBI chr X:16,485,937...16,554,051
Ensembl chr X:16,485,937...16,554,057
|
|
G |
Npy1r |
neuropeptide Y receptor Y1 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of NPY1R mRNA |
CTD |
PMID:33404927 |
|
NCBI chr 8:67,149,595...67,159,452
Ensembl chr 8:67,149,844...67,159,444
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase family, member 1 |
increases expression multiple interactions |
ISO |
ammonium acetate results in increased expression of PARP1 protein Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein]; Dizocilpine Maleate inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein] |
CTD |
PMID:15147502 |
|
NCBI chr 1:180,396,456...180,428,564
Ensembl chr 1:180,396,489...180,428,819
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
increases expression |
ISO |
ammonium acetate results in increased expression of PPP1CC protein |
CTD |
PMID:33404927 |
|
NCBI chr 5:122,296,338...122,313,336
Ensembl chr 5:122,296,341...122,313,336
|
|
G |
Slc8a2 |
solute carrier family 8 (sodium/calcium exchanger), member 2 |
decreases expression |
ISO |
ammonium acetate results in decreased expression of SLC8A2 protein |
CTD |
PMID:33404927 |
|
NCBI chr 7:15,861,540...15,894,988
Ensembl chr 7:15,863,751...15,894,988
|
|
G |
Sod2 |
superoxide dismutase 2, mitochondrial |
decreases activity multiple interactions |
ISO |
ammonium acetate results in decreased activity of SOD2 protein Dizocilpine Maleate inhibits the reaction [ammonium acetate results in decreased activity of SOD2 protein] |
CTD |
PMID:12885441 |
|
NCBI chr17:13,226,726...13,237,006
Ensembl chr17:13,225,733...13,258,950
|
|
G |
Xdh |
xanthine dehydrogenase |
affects activity multiple interactions |
ISO |
ammonium acetate affects the activity of XDH protein Dizocilpine Maleate inhibits the reaction [ammonium acetate affects the activity of XDH protein] |
CTD |
PMID:12885441 |
|
NCBI chr17:74,190,890...74,257,191
Ensembl chr17:74,190,890...74,257,191
|
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
increases expression |
ISO |
cobalt(II) acetate results in increased expression of HIF1A protein |
CTD |
PMID:16357179 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
EXP |
lead tetraacetate results in decreased expression of APP mRNA |
CTD |
PMID:20865013 |
|
NCBI chr16:84,751,236...84,972,187
Ensembl chr16:84,746,573...84,970,654
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
EXP |
lead tetraacetate results in decreased expression of MAPT mRNA |
CTD |
PMID:20865013 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Nrxn1 |
neurexin I |
decreases expression |
EXP |
lead tetraacetate results in decreased expression of NRXN1 mRNA |
CTD |
PMID:20865013 |
|
NCBI chr17:90,341,072...91,400,587
Ensembl chr17:90,341,059...91,400,499
|
|
G |
Prnp |
prion protein |
decreases expression |
EXP |
lead tetraacetate results in decreased expression of PRNP mRNA |
CTD |
PMID:20865013 |
|
NCBI chr 2:131,751,848...131,780,356
Ensembl chr 2:131,751,848...131,780,349
|
|
G |
Syp |
synaptophysin |
decreases expression |
EXP |
lead tetraacetate results in decreased expression of SYP mRNA |
CTD |
PMID:20865013 |
|
NCBI chr X:7,504,819...7,519,495
Ensembl chr X:7,504,710...7,519,495
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
decreases expression |
EXP |
lead tetraacetate results in decreased expression of TUBB3 mRNA |
CTD |
PMID:20865013 |
|
NCBI chr 8:124,138,292...124,148,754
Ensembl chr 8:124,138,163...124,148,754
|
|
|
G |
Alkbh5 |
alkB homolog 5, RNA demethylase |
decreases expression multiple interactions |
ISO |
thallium acetate results in decreased expression of ALKBH5 protein 3-deazaadenosine inhibits the reaction [thallium acetate results in decreased expression of ALKBH5 protein]; ALKBH5 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein] |
CTD |
PMID:36745568 |
|
NCBI chr11:60,428,509...60,449,338
Ensembl chr11:60,427,207...60,449,338
|
|
G |
Atp13a3 |
ATPase type 13A3 |
multiple interactions increases expression increases stability |
ISO |
3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of and results in increased methylation of ATP13A3 mRNA]; 3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of ATP13A3 protein]; ALKBH5 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]; METTL14 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]; METTL3 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein]; thallium acetate results in increased expression of and results in increased methylation of ATP13A3 mRNA thallium acetate results in increased stability of ATP13A3 mRNA |
CTD |
PMID:36745568 |
|
NCBI chr16:30,131,241...30,207,674
Ensembl chr16:30,131,241...30,224,793
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
thallium acetate results in increased expression of H2AX protein |
CTD |
PMID:36745568 |
|
NCBI chr 9:44,246,012...44,247,374
Ensembl chr 9:44,245,991...44,247,374
|
|
G |
Mettl14 |
methyltransferase 14, N6-adenosine-methyltransferase subunit |
multiple interactions increases expression |
ISO |
3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of METTL14 protein]; METTL14 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein] |
CTD |
PMID:36745568 |
|
NCBI chr 3:123,161,944...123,179,639
Ensembl chr 3:123,161,946...123,179,757
|
|
G |
Mettl3 |
methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit |
multiple interactions increases expression |
ISO |
3-deazaadenosine inhibits the reaction [thallium acetate results in increased expression of METTL3 protein]; METTL3 protein affects the reaction [thallium acetate results in increased expression of ATP13A3 protein] |
CTD |
PMID:36745568 |
|
NCBI chr14:52,532,298...52,548,555
Ensembl chr14:52,532,298...52,542,585
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
decreases activity |
ISO |
thallium acetate results in decreased activity of SOD1 protein |
CTD |
PMID:15833379 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
|
G |
Abcb11 |
ATP-binding cassette, sub-family B member 11 |
multiple interactions |
EXP |
[ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [NR1H4 protein binds to ABCB11 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [RXRA protein binds to ABCB11 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] which results in increased expression of ABCB11 mRNA |
CTD |
PMID:26241054 |
|
NCBI chr 2:69,068,626...69,172,960
Ensembl chr 2:69,068,626...69,172,958
|
|
G |
Agl |
amylo-1,6-glucosidase, 4-alpha-glucanotransferase |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of AGL mRNA Zinc Acetate results in decreased expression of AGL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:116,533,648...116,601,815
Ensembl chr 3:116,533,648...116,601,815
|
|
G |
Alad |
aminolevulinate, delta-, dehydratase |
increases activity multiple interactions |
ISO |
Zinc Acetate results in increased activity of ALAD protein [Zinc Acetate results in increased activity of ALAD protein] which results in increased chemical synthesis of Porphobilinogen; Zinc Acetate inhibits the reaction [Dithiothreitol results in increased activity of ALAD protein] |
CTD |
PMID:21360559 |
|
NCBI chr 4:62,422,762...62,438,300
Ensembl chr 4:62,427,406...62,438,155
|
|
G |
Aldh5a1 |
aldhehyde dehydrogenase family 5, subfamily A1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of ALDH5A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr13:25,091,562...25,121,740
Ensembl chr13:25,091,562...25,121,644
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase family 6, subfamily A1 |
multiple interactions increases expression |
ISO |
Zinc Acetate inhibits the reaction [motexafin gadolinium results in decreased expression of ALDH6A1 mRNA] Zinc Acetate results in increased expression of ALDH6A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:84,477,491...84,497,798
Ensembl chr12:84,477,491...84,497,778
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ARHGAP17 mRNA Zinc Acetate results in decreased expression of ARHGAP17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:122,878,372...122,969,171
Ensembl chr 7:122,878,441...122,969,138
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of ATF3 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 1:190,902,493...190,915,530
Ensembl chr 1:190,902,493...190,950,236
|
|
G |
Atm |
ataxia telangiectasia mutated |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of ATM mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 9:53,348,422...53,448,125
Ensembl chr 9:53,350,449...53,448,040
|
|
G |
Atp7b |
ATPase, Cu++ transporting, beta polypeptide |
increases response to substance multiple interactions |
EXP |
ATP7B gene mutant form results in increased susceptibility to Zinc Acetate [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [NR1H4 protein binds to ABCB11 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [RXRA protein binds to ABCB11 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [RXRA protein binds to NR0B2 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] which results in increased expression of ABCB11 mRNA; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] which results in increased expression of NR0B2 mRNA; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] which results in increased expression of RXRA mRNA |
CTD |
PMID:26241054 |
|
NCBI chr 8:22,482,799...22,550,347
Ensembl chr 8:22,482,801...22,550,321
|
|
G |
Atr |
ataxia telangiectasia and Rad3 related |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ATR mRNA Zinc Acetate results in decreased expression of ATR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:95,739,655...95,834,813
Ensembl chr 9:95,739,650...95,833,834
|
|
G |
Bach1 |
BTB and CNC homology 1, basic leucine zipper transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BACH1 mRNA Zinc Acetate results in increased expression of BACH1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:87,495,842...87,530,234
Ensembl chr16:87,495,833...87,530,234
|
|
G |
Bag3 |
BCL2-associated athanogene 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of BAG3 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:128,125,307...128,148,705
Ensembl chr 7:128,125,340...128,148,705
|
|
G |
Bbc3 |
BCL2 binding component 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 7:16,042,307...16,052,130
Ensembl chr 7:16,042,318...16,052,130
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of BIRC5 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of BIRC5 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr11:117,740,063...117,746,569
Ensembl chr11:117,740,077...117,746,569
|
|
G |
Bmt2 |
base methyltransferase of 25S rRNA 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BMT2 mRNA Zinc Acetate results in increased expression of BMT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:13,625,674...13,677,965
Ensembl chr 6:13,625,672...13,677,965
|
|
G |
Bnip3 |
BCL2/adenovirus E1B interacting protein 3 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3 mRNA Zinc Acetate results in increased expression of BNIP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:138,492,565...138,511,235
Ensembl chr 7:138,492,565...138,511,248
|
|
G |
Bnip3l |
BCL2/adenovirus E1B interacting protein 3-like |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3L mRNA Zinc Acetate results in increased expression of BNIP3L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:67,222,688...67,246,580
Ensembl chr14:67,222,688...67,246,326
|
|
G |
Bsg |
basigin |
multiple interactions |
EXP |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of BSG protein] |
CTD |
PMID:34508822 |
|
NCBI chr10:79,540,192...79,547,813
Ensembl chr10:79,540,325...79,547,803
|
|
G |
Canx |
calnexin |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of CANX mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CANX mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:50,184,784...50,216,500
Ensembl chr11:50,184,788...50,216,500
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression |
ISO |
[Taurine co-treated with Zinc Acetate] inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein] [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CASP3 mRNA Zinc Acetate results in decreased expression of CASP3 mRNA |
CTD |
PMID:16357179 PMID:26335259 |
|
NCBI chr 8:47,070,326...47,092,733
Ensembl chr 8:47,070,326...47,092,724
|
|
G |
Cbfb |
core binding factor beta |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of CBFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CBFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:105,897,306...105,944,621
Ensembl chr 8:105,897,306...105,944,621
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CCNB1 protein] |
CTD |
PMID:36162444 |
|
NCBI chr13:100,915,247...100,922,994
Ensembl chr13:100,915,158...100,923,078
|
|
G |
Ccnj |
cyclin J |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CCNJ mRNA Zinc Acetate results in decreased expression of CCNJ mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:40,819,345...40,837,016
Ensembl chr19:40,819,723...40,837,016
|
|
G |
Cdc16 |
CDC16 cell division cycle 16 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC16 mRNA Zinc Acetate results in decreased expression of CDC16 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:13,807,650...13,831,951
Ensembl chr 8:13,807,676...13,831,938
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDC25C mRNA Zinc Acetate results in increased expression of CDC25C mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:34,866,046...34,884,644
Ensembl chr18:34,866,046...34,884,586
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of CDC27 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CDC27 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:104,393,350...104,441,371
Ensembl chr11:104,393,571...104,441,446
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression multiple interactions |
ISO |
Zinc Acetate results in decreased expression of CDC5L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC5L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:45,702,809...45,744,633
Ensembl chr17:45,702,810...45,744,663
|
|
G |
Cdca2 |
cell division cycle associated 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDCA2 mRNA Zinc Acetate results in decreased expression of CDCA2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:67,910,629...67,953,290
Ensembl chr14:67,913,780...67,953,290
|
|
G |
Cdk19 |
cyclin dependent kinase 19 |
increases expression |
ISO |
Zinc Acetate results in increased expression of CDK19 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:40,225,283...40,359,814
Ensembl chr10:40,215,560...40,359,814
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of CDK2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:128,533,807...128,540,920
Ensembl chr10:128,533,808...128,540,900
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr17:29,309,953...29,319,696
Ensembl chr17:29,309,950...29,319,701
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDKN1B mRNA Zinc Acetate results in increased expression of CDKN1B mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:134,897,364...134,902,488
Ensembl chr 6:134,897,364...134,902,476
|
|
G |
Cth |
cystathionine gamma lyase |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of CTH mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CTH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:157,599,885...157,630,718
Ensembl chr 3:157,599,885...157,630,714
|
|
G |
Cul3 |
cullin 3 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CUL3 mRNA Zinc Acetate results in decreased expression of CUL3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:80,242,640...80,318,426
Ensembl chr 1:80,242,640...80,318,197
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases secretion |
ISO |
Zinc Acetate results in increased secretion of CXCL1 protein |
CTD |
PMID:21974847 |
|
NCBI chr 5:91,039,104...91,040,980
Ensembl chr 5:91,039,100...91,040,974
|
|
G |
Cxcl15 |
C-X-C motif chemokine ligand 15 |
multiple interactions increases secretion increases expression |
ISO |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Zinc Acetate results in increased expression of CXCL8 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Zinc Acetate results in increased expression of CXCL8 protein]; MYD88 mutant form inhibits the reaction [Zinc Acetate results in increased expression of CXCL8 protein] Zinc Acetate results in increased secretion of CXCL8 protein |
CTD |
PMID:21974847 PMID:24080332 |
|
NCBI chr 5:90,942,393...90,950,926
Ensembl chr 5:90,942,393...90,950,926
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases secretion |
ISO |
Zinc Acetate results in increased secretion of CXCL1 protein |
CTD |
PMID:21974847 |
|
NCBI chr 5:90,933,960...90,935,952
Ensembl chr 5:90,933,962...90,937,459
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of CYB5R1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CYB5R1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:134,333,519...134,339,476
Ensembl chr 1:134,333,297...134,339,478
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of DAPK3 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DAPK3 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:81,018,821...81,029,031
Ensembl chr10:81,018,839...81,029,031
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DDIT3 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:127,126,662...127,132,160
Ensembl chr10:127,126,643...127,132,157 Ensembl chr10:127,126,643...127,132,157
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of DDIT4 mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of DDIT4 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:59,785,497...59,787,592
Ensembl chr10:59,785,491...59,787,656
|
|
G |
Dedd2 |
death effector domain-containing DNA binding protein 2 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of DEDD2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DEDD2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:24,899,337...24,920,035
Ensembl chr 7:24,899,340...24,920,040
|
|
G |
Dffb |
DNA fragmentation factor, beta subunit |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of DFFB mRNA Zinc Acetate results in decreased expression of DFFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:154,048,904...154,059,578
Ensembl chr 4:154,048,906...154,059,583
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:143,376,827...143,402,147
Ensembl chr 7:143,376,882...143,402,147
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression multiple interactions |
ISO |
Zinc Acetate results in decreased expression of DNAJB1 mRNA motexafin gadolinium inhibits the reaction [Zinc Acetate results in decreased expression of DNAJB1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 8:84,334,804...84,339,282
Ensembl chr 8:84,334,822...84,339,282
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB4 mRNA Zinc Acetate results in increased expression of DNAJB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:151,887,217...151,915,720
Ensembl chr 3:151,884,148...151,915,939
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB6 mRNA Zinc Acetate results in increased expression of DNAJB6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:29,940,896...29,991,476
Ensembl chr 5:29,940,686...30,023,132
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of DNAJC3 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr14:119,175,371...119,219,114
Ensembl chr14:119,175,388...119,219,109
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
Zinc Acetate inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:9109525 |
|
NCBI chr13:54,205,202...54,209,677
Ensembl chr13:54,205,202...54,209,724
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Zinc Acetate inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] |
CTD |
PMID:9109525 |
|
NCBI chr 9:49,251,703...49,319,468
Ensembl chr 9:49,251,927...49,319,477
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[Taurine co-treated with Zinc Acetate] results in increased expression of DUSP1 mRNA; [Taurine co-treated with Zinc Acetate] results in increased expression of DUSP1 protein |
CTD |
PMID:26335259 |
|
NCBI chr17:26,724,565...26,727,446
Ensembl chr17:26,724,564...26,781,102
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of E2F1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:154,401,320...154,411,812
Ensembl chr 2:154,401,327...154,411,812
|
|
G |
E2f3 |
E2F transcription factor 3 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA Zinc Acetate results in increased expression of E2F3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:30,090,558...30,171,172
Ensembl chr13:30,090,558...30,170,046
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of EGLN1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of EGLN1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:125,635,325...125,676,063
Ensembl chr 8:125,635,326...125,676,063
|
|
G |
Elp1 |
elongator complex protein 1 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ELP1 mRNA Zinc Acetate results in decreased expression of ELP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:56,746,547...56,802,565
Ensembl chr 4:56,749,680...56,802,331
|
|
G |
Eno1 |
enolase 1, alpha non-neuron |
increases expression |
ISO |
Zinc Acetate results in increased expression of ENO1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:150,321,165...150,333,336
Ensembl chr 4:150,321,178...150,333,336
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FADD mRNA Zinc Acetate results in decreased expression of FADD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:144,132,060...144,136,178
Ensembl chr 7:144,131,055...144,136,200
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FAIM mRNA Zinc Acetate results in decreased expression of FAIM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:98,868,426...98,884,076
Ensembl chr 9:98,868,426...98,884,074
|
|
G |
Fam162a |
family with sequence similarity 162, member A |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FAM162A mRNA Zinc Acetate results in increased expression of FAM162A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:35,864,214...35,891,931
Ensembl chr16:35,864,131...35,891,964
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of FASN mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:120,696,784...120,715,992
Ensembl chr11:120,696,672...120,715,373
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FOXO3 mRNA Zinc Acetate results in increased expression of FOXO3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:42,057,841...42,152,691
Ensembl chr10:42,057,837...42,152,751
|
|
G |
Gclm |
glutamate-cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of GCLM mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GCLM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:122,039,206...122,060,864
Ensembl chr 3:122,039,206...122,064,381
|
|
G |
Gls |
glutaminase |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GLS mRNA Zinc Acetate results in decreased expression of GLS mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:52,202,608...52,274,168
Ensembl chr 1:52,202,607...52,272,391
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
increases expression |
ISO |
Zinc Acetate results in increased expression of GPR146 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:139,363,452...139,382,170
Ensembl chr 5:139,363,452...139,382,170
|
|
G |
Gpt2 |
glutamic pyruvate transaminase (alanine aminotransferase) 2 |
increases expression |
ISO |
Zinc Acetate results in increased expression of GPT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:86,219,090...86,255,531
Ensembl chr 8:86,219,205...86,254,189
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr 9:108,216,279...108,217,541
Ensembl chr 9:108,216,102...108,217,542
|
|
G |
Gsr |
glutathione reductase |
multiple interactions decreases activity increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GSR mRNA Zinc Acetate results in decreased activity of GSR protein Zinc Acetate results in increased expression of GSR mRNA |
CTD |
PMID:16357179 PMID:17382203 |
|
NCBI chr 8:34,143,266...34,188,190
Ensembl chr 8:34,142,551...34,188,191
|
|
G |
Gtf3c2 |
general transcription factor IIIC, polypeptide 2, beta |
increases expression |
ISO |
Zinc Acetate results in increased expression of GTF3C2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:31,313,350...31,337,488
Ensembl chr 5:31,313,349...31,337,488
|
|
G |
Hbp1 |
high mobility group box transcription factor 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of HBP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HBP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:31,976,449...32,000,529
Ensembl chr12:31,976,253...32,000,534
|
|
G |
Hif1a |
hypoxia inducible factor 1, alpha subunit |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HIF1A protein Zinc Acetate results in increased expression of HIF1A protein |
CTD |
PMID:16357179 |
|
NCBI chr12:73,948,186...73,994,304
Ensembl chr12:73,948,149...73,994,304
|
|
G |
Hilpda |
hypoxia inducible lipid droplet associated |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HILPDA mRNA Zinc Acetate results in increased expression of HILPDA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:29,272,487...29,275,448
Ensembl chr 6:29,272,487...29,275,445
|
|
G |
Hipk1 |
homeodomain interacting protein kinase 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HIPK1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 3:103,647,131...103,699,210
Ensembl chr 3:103,647,131...103,698,879
|
|
G |
Hltf |
helicase-like transcription factor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of HLTF mRNA Zinc Acetate results in decreased expression of HLTF mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:20,111,959...20,172,655
Ensembl chr 3:20,111,975...20,172,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HMOX1 protein; motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HMOX1 mRNA] [Taurine co-treated with Zinc Acetate] results in increased expression of HMOX1 protein |
CTD |
PMID:16357179 PMID:26335259 |
|
NCBI chr 8:75,820,246...75,827,221
Ensembl chr 8:75,820,249...75,827,217
|
|
G |
Hrk |
harakiri, BCL2 interacting protein (contains only BH3 domain) |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of HRK mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HRK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:118,307,829...118,327,543
Ensembl chr 5:118,302,713...118,327,543
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha (cytosolic), class B member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSP90AB1 mRNA Zinc Acetate results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:45,878,704...45,884,187
Ensembl chr17:45,878,701...45,884,197
|
|
G |
Hspa1a |
heat shock protein 1A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1A mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr17:35,188,335...35,191,132
Ensembl chr17:35,188,166...35,191,132
|
|
G |
Hspa1b |
heat shock protein 1B |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1B mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1B mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr17:35,175,405...35,178,214
Ensembl chr17:35,175,412...35,178,214
|
|
G |
Hspa4 |
heat shock protein 4 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4 mRNA Zinc Acetate results in increased expression of HSPA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:53,150,641...53,191,306
Ensembl chr11:53,150,641...53,191,284
|
|
G |
Hspa4l |
heat shock protein 4 like |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA Zinc Acetate results in increased expression of HSPA4L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:40,698,664...40,750,538
Ensembl chr 3:40,699,814...40,750,538
|
|
G |
Hspb1 |
heat shock protein 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPB1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 5:135,916,773...135,918,417
Ensembl chr 5:135,916,773...135,918,417
|
|
G |
Hspd1 |
heat shock protein 1 (chaperonin) |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPD1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 1:55,116,992...55,127,402
Ensembl chr 1:55,116,994...55,127,402
|
|
G |
Hsph1 |
heat shock 105kDa/110kDa protein 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPH1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 5:149,540,308...149,562,594
Ensembl chr 5:149,537,752...149,559,841
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Zinc Acetate results in increased expression of ICAM1 protein]; [Zinc Acetate results in increased phosphorylation of NFKBIA protein] inhibits the reaction [Zinc Acetate results in increased expression of ICAM1 protein]; MYD88 mutant form inhibits the reaction [Zinc Acetate results in increased expression of ICAM1 protein] |
CTD |
PMID:24080332 |
|
NCBI chr 9:20,927,236...20,940,110
Ensembl chr 9:20,927,281...20,940,113
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of ID2 mRNA Zinc Acetate results in increased expression of ID2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:25,143,798...25,146,091
Ensembl chr12:25,143,798...25,147,139
|
|
G |
Ikbke |
inhibitor of kappaB kinase epsilon |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IKBKE mRNA Zinc Acetate results in increased expression of IKBKE mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:131,182,337...131,207,339
Ensembl chr 1:131,182,080...131,207,344
|
|
G |
Il10 |
interleukin 10 |
increases secretion |
ISO |
Zinc Acetate results in increased secretion of IL10 protein |
CTD |
PMID:21974847 |
|
NCBI chr 1:130,947,459...130,952,707
Ensembl chr 1:130,947,582...130,952,711
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Taurine co-treated with Zinc Acetate] results in decreased expression of IL1B protein |
CTD |
PMID:27501764 |
|
NCBI chr 2:129,206,490...129,213,059
Ensembl chr 2:129,206,490...129,213,059
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
Zinc Acetate results in increased secretion of IL6 protein |
CTD |
PMID:21974847 |
|
NCBI chr 5:30,218,112...30,224,973
Ensembl chr 5:30,218,112...30,224,979
|
|
G |
Il7 |
interleukin 7 |
increases secretion |
ISO |
Zinc Acetate results in increased secretion of IL7 protein |
CTD |
PMID:21974847 |
|
NCBI chr 3:7,637,088...7,678,820
Ensembl chr 3:7,635,054...7,678,820
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IRF2BP2 mRNA Zinc Acetate results in increased expression of IRF2BP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:127,315,035...127,320,725
Ensembl chr 8:127,315,035...127,320,725
|
|
G |
Jund |
jun D proto-oncogene |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of JUND mRNA Zinc Acetate results in increased expression of JUND mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:71,150,389...71,153,265
Ensembl chr 8:71,151,599...71,153,265
|
|
G |
Kdm3a |
lysine (K)-specific demethylase 3A |
increases expression |
ISO |
Zinc Acetate results in increased expression of KDM3A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:71,565,954...71,609,963
Ensembl chr 6:71,565,956...71,609,974
|
|
G |
Klra17 |
killer cell lectin-like receptor, subfamily A, member 17 |
increases expression |
ISO |
Zinc Acetate results in increased expression of ZNF302 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:129,808,117...129,853,635
Ensembl chr 6:129,808,117...129,853,635
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Taurine co-treated with Zinc Acetate] results in decreased expression of MAPK8 protein modified form |
CTD |
PMID:27501764 |
|
NCBI chr14:33,099,855...33,169,213
Ensembl chr14:33,099,855...33,169,115
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Taurine co-treated with Zinc Acetate] results in decreased expression of MAPK9 protein modified form |
CTD |
PMID:27501764 |
|
NCBI chr11:49,737,558...49,777,248
Ensembl chr11:49,737,578...49,777,248
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
[Zinc Acetate results in decreased abundance of Copper] which results in decreased phosphorylation of MAPT protein |
CTD |
PMID:25671100 |
|
NCBI chr11:104,120,235...104,222,916
Ensembl chr11:104,122,216...104,222,916
|
|
G |
Mdm2 |
transformed mouse 3T3 cell double minute 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr10:117,524,780...117,546,663
Ensembl chr10:117,524,780...117,546,663
|
|
G |
Mob1a |
MOB kinase activator 1A |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of MOB1A mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MOB1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 6:83,303,016...83,320,758
Ensembl chr 6:83,302,998...83,320,758
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
EXP ISO |
Zinc Acetate results in increased expression of MT1 protein Zinc Acetate results in increased expression of MT1X mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT1X mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of MT1X mRNA] |
CTD |
PMID:15306638 PMID:16357179 |
|
NCBI chr 8:94,905,214...94,906,955
Ensembl chr 8:94,905,710...94,906,955
|
|
G |
Mt2 |
metallothionein 2 |
increases expression multiple interactions |
EXP ISO |
Zinc Acetate results in increased expression of MT2 mRNA; Zinc Acetate results in increased expression of MT2 protein Zinc Acetate results in increased expression of MT2A mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT2A mRNA] |
CTD |
PMID:8876661 PMID:15306638 PMID:16357179 |
|
NCBI chr 8:94,899,246...94,900,195
Ensembl chr 8:94,899,292...94,900,196
|
|
G |
Myd88 |
myeloid differentiation primary response gene 88 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of MYD88 mRNA; MYD88 mutant form inhibits the reaction [Zinc Acetate results in increased expression of CXCL8 protein]; MYD88 mutant form inhibits the reaction [Zinc Acetate results in increased expression of ICAM1 protein] Zinc Acetate results in decreased expression of MYD88 mRNA |
CTD |
PMID:16357179 PMID:24080332 |
|
NCBI chr 9:119,165,000...119,169,084
Ensembl chr 9:119,165,000...119,170,477
|
|
G |
Nadk |
NAD kinase |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NADK mRNA Zinc Acetate results in increased expression of NADK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:155,646,838...155,675,458
Ensembl chr 4:155,646,835...155,675,458
|
|
G |
Nf1 |
neurofibromin 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of NF1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NF1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:79,223,541...79,472,435
Ensembl chr11:79,230,519...79,472,438
|
|
G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha |
increases degradation increases phosphorylation multiple interactions |
ISO |
Zinc Acetate results in increased degradation of NFKBIA protein Zinc Acetate results in increased phosphorylation of NFKBIA protein [Zinc Acetate results in increased phosphorylation of NFKBIA protein] inhibits the reaction [Zinc Acetate results in increased expression of ICAM1 protein] |
CTD |
PMID:21974847 PMID:24080332 |
|
NCBI chr12:55,536,194...55,539,432
Ensembl chr12:55,536,195...55,539,432
|
|
G |
Nisch |
nischarin |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of NISCH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:30,892,885...30,928,783
Ensembl chr14:30,892,887...30,938,903
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
EXP |
[ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [RXRA protein binds to NR0B2 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] which results in increased expression of NR0B2 mRNA |
CTD |
PMID:26241054 |
|
NCBI chr 4:133,280,687...133,283,997
Ensembl chr 4:133,280,687...133,283,847
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of NR1D2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr14:4,230,549...4,265,639
Ensembl chr14:4,230,569...4,265,642
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
[ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [NR1H4 protein binds to ABCB11 promoter] |
CTD |
PMID:26241054 |
|
NCBI chr10:89,290,096...89,369,484
Ensembl chr10:89,290,096...89,369,447
|
|
G |
P4hb |
prolyl 4-hydroxylase, beta polypeptide |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of P4HB mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr11:120,451,124...120,464,079
Ensembl chr11:120,451,124...120,464,079
|
|
G |
Pdcd11 |
programmed cell death 11 |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of PDCD11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:47,079,183...47,119,585
Ensembl chr19:47,079,207...47,120,304
|
|
G |
Pdcd4 |
programmed cell death 4 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PDCD4 mRNA Zinc Acetate results in increased expression of PDCD4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:53,880,662...53,926,024
Ensembl chr19:53,880,662...53,918,291
|
|
G |
Pdcd5 |
programmed cell death 5 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PDCD5 mRNA Zinc Acetate results in decreased expression of PDCD5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:35,341,410...35,346,907
Ensembl chr 7:35,341,407...35,346,946
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB3 mRNA Zinc Acetate results in increased expression of PFKFB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:11,476,241...11,558,882
Ensembl chr 2:11,476,244...11,558,888
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB4 mRNA Zinc Acetate results in increased expression of PFKFB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:108,817,336...108,861,302
Ensembl chr 9:108,820,846...108,861,296
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
EXP |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of PFKM protein] |
CTD |
PMID:34508822 |
|
NCBI chr15:97,990,470...98,030,328
Ensembl chr15:97,990,470...98,030,332
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of PGK1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PGK1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr X:105,230,706...105,247,305
Ensembl chr X:105,230,706...105,247,305
|
|
G |
Phtf2 |
putative homeodomain transcription factor 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PHTF2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 5:20,963,662...21,087,122
Ensembl chr 5:20,963,661...21,087,122
|
|
G |
Pias1 |
protein inhibitor of activated STAT 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PIAS1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 9:62,785,648...62,888,161
Ensembl chr 9:62,785,650...62,895,206
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PIK3IP1 mRNA Zinc Acetate results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:3,280,731...3,292,971
Ensembl chr11:3,280,401...3,292,971
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of PMAIP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:66,591,675...66,598,629
Ensembl chr18:66,591,604...66,598,636
|
|
G |
Prkacb |
protein kinase, cAMP dependent, catalytic, beta |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PRKACB mRNA Zinc Acetate results in increased expression of PRKACB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:146,435,334...146,518,691
Ensembl chr 3:146,435,329...146,518,745
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of PRKCD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:30,317,310...30,348,637
Ensembl chr14:30,317,311...30,348,167
|
|
G |
Prkd2 |
protein kinase D2 |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of PRKD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:16,576,827...16,604,386
Ensembl chr 7:16,576,827...16,604,389
|
|
G |
Prkdc |
protein kinase, DNA activated, catalytic polypeptide |
increases expression |
ISO |
Zinc Acetate results in increased expression of PRKDC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:15,455,698...15,660,103
Ensembl chr16:15,455,730...15,660,099
|
|
G |
Ptrh2 |
peptidyl-tRNA hydrolase 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PTRH2 mRNA Zinc Acetate results in decreased expression of PTRH2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:86,574,900...86,583,283
Ensembl chr11:86,574,811...86,583,283
|
|
G |
Pttg1 |
pituitary tumor-transforming gene 1 |
multiple interactions |
ISO |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of PTTG1 protein] |
CTD |
PMID:36162444 |
|
NCBI chr11:43,311,097...43,317,417
Ensembl chr11:43,311,077...43,317,078
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RB1 mRNA Zinc Acetate results in decreased expression of RB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:73,430,298...73,563,446
Ensembl chr14:73,421,113...73,563,262
|
|
G |
Rcbtb2 |
regulator of chromosome condensation (RCC1) and BTB (POZ) domain containing protein 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RCBTB2 mRNA Zinc Acetate results in decreased expression of RCBTB2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:73,376,185...73,421,495
Ensembl chr14:73,360,477...73,445,283
|
|
G |
Relb |
avian reticuloendotheliosis viral (v-rel) oncogene related B |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of RELB mRNA Zinc Acetate results in increased expression of RELB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:19,340,142...19,363,352
Ensembl chr 7:19,340,142...19,363,363
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
EXP |
[ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [RXRA protein binds to ABCB11 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] promotes the reaction [RXRA protein binds to NR0B2 promoter]; [ATP7B gene mutant form results in increased susceptibility to Zinc Acetate] which results in increased expression of RXRA mRNA |
CTD |
PMID:26241054 |
|
NCBI chr 2:27,566,457...27,653,331
Ensembl chr 2:27,566,452...27,652,969
|
|
G |
Selenow |
selenoprotein W |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SELENOW mRNA Zinc Acetate results in increased expression of SELENOW mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:15,651,133...15,656,296
Ensembl chr 7:15,651,133...15,656,327
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA; [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SESN2 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA] Zinc Acetate results in increased expression of SESN2 mRNA |
CTD |
PMID:16357179 PMID:20530418 |
|
NCBI chr 4:132,220,115...132,237,767
Ensembl chr 4:132,219,343...132,237,812
|
|
G |
Slc16a1 |
solute carrier family 16 (monocarboxylic acid transporters), member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC16A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 3:104,545,980...104,565,778
Ensembl chr 3:104,545,984...104,565,778
|
|
G |
Slc16a3 |
solute carrier family 16 (monocarboxylic acid transporters), member 3 |
multiple interactions |
EXP |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of SLC16A3 protein] |
CTD |
PMID:34508822 |
|
NCBI chr11:120,839,310...120,849,826
Ensembl chr11:120,839,306...120,851,694
|
|
G |
Slc16a6 |
solute carrier family 16 (monocarboxylic acid transporters), member 6 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of SLC16A6 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:109,341,681...109,366,428
Ensembl chr11:109,341,681...109,364,424
|
|
G |
Slc1a4 |
solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of SLC1A4 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC1A4 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr11:20,252,180...20,282,713
Ensembl chr11:20,252,180...20,282,713
|
|
G |
Slc2a1 |
solute carrier family 2 (facilitated glucose transporter), member 1 |
multiple interactions |
EXP |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of SLC2A1 protein] |
CTD |
PMID:34508822 |
|
NCBI chr 4:118,966,001...118,994,527
Ensembl chr 4:118,965,908...118,995,180
|
|
G |
Slc30a1 |
solute carrier family 30 (zinc transporter), member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC30A1 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 1:191,638,810...191,645,359
Ensembl chr 1:191,638,879...191,645,359
|
|
G |
Slc31a1 |
solute carrier family 31, member 1 |
increases expression |
ISO |
Zinc Acetate results in increased expression of SLC31A1 mRNA |
CTD |
PMID:24132751 |
|
NCBI chr 4:62,278,821...62,310,006
Ensembl chr 4:62,278,964...62,310,006
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC38A2 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr15:96,585,267...96,597,609
Ensembl chr15:96,585,273...96,597,611
|
|
G |
Slc39a10 |
solute carrier family 39 (zinc transporter), member 10 |
affects expression multiple interactions |
ISO |
Zinc Acetate affects the expression of SLC39A10 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A10 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:46,846,704...46,964,952
Ensembl chr 1:46,846,704...46,932,012
|
|
G |
Slc39a14 |
solute carrier family 39 (zinc transporter), member 14 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A14 mRNA Zinc Acetate results in increased expression of SLC39A14 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:70,540,916...70,588,873
Ensembl chr14:70,540,918...70,588,874
|
|
G |
Slc39a9 |
solute carrier family 39 (zinc transporter), member 9 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC39A9 mRNA Zinc Acetate results in increased expression of SLC39A9 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:80,690,657...80,730,116
Ensembl chr12:80,690,657...80,730,116
|
|
G |
Slc3a2 |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC3A2 mRNA Zinc Acetate results in increased expression of SLC3A2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:8,684,931...8,700,733
Ensembl chr19:8,684,246...8,700,733
|
|
G |
Slc43a1 |
solute carrier family 43, member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC43A1 mRNA Zinc Acetate results in increased expression of SLC43A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:84,669,196...84,693,930
Ensembl chr 2:84,669,194...84,693,938
|
|
G |
Slc7a1 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A1 mRNA Zinc Acetate results in increased expression of SLC7A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:148,264,220...148,336,714
Ensembl chr 5:148,264,220...148,336,714
|
|
G |
Slc7a11 |
solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A11 mRNA Zinc Acetate results in increased expression of SLC7A11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:50,319,385...50,403,947
Ensembl chr 3:49,846,975...50,398,063
|
|
G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA4 mRNA Zinc Acetate results in decreased expression of SMARCA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:21,527,377...21,615,526
Ensembl chr 9:21,527,465...21,615,526
|
|
G |
Smarca5 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA5 mRNA Zinc Acetate results in decreased expression of SMARCA5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:81,426,572...81,466,088
Ensembl chr 8:81,425,136...81,466,126
|
|
G |
Sod1 |
superoxide dismutase 1, soluble |
multiple interactions |
EXP |
[Zinc Acetate results in increased abundance of Zinc] inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of SOD1 protein] |
CTD |
PMID:34508822 |
|
NCBI chr16:90,017,650...90,023,221
Ensembl chr16:90,017,642...90,023,217
|
|
G |
Sp1 |
trans-acting transcription factor 1 |
increases expression |
ISO |
Zinc Acetate results in increased expression of SP1 mRNA |
CTD |
PMID:24132751 |
|
NCBI chr15:102,314,751...102,344,839
Ensembl chr15:102,314,578...102,344,839
|
|
G |
Tagap |
T cell activation Rho GTPase activating protein |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TAGAP mRNA Zinc Acetate results in increased expression of TAGAP mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:8,144,832...8,153,729
Ensembl chr17:8,144,832...8,153,729
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of TFRC mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr16:32,427,714...32,451,612
Ensembl chr16:32,427,738...32,451,612
|
|
G |
Tnfaip8 |
tumor necrosis factor, alpha-induced protein 8 |
decreases expression multiple interactions |
ISO |
Zinc Acetate results in decreased expression of TNFAIP8 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFAIP8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:50,112,494...50,226,296
Ensembl chr18:50,112,494...50,240,240
|
|
G |
Tnfrsf17 |
tumor necrosis factor receptor superfamily, member 17 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFRSF17 mRNA Zinc Acetate results in decreased expression of TNFRSF17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:11,131,131...11,137,938
Ensembl chr16:11,131,676...11,137,938
|
|
G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of TNFRSF1A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:125,326,686...125,339,446
Ensembl chr 6:125,326,325...125,339,447
|
|
G |
Tnfsf8 |
tumor necrosis factor (ligand) superfamily, member 8 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of TNFSF8 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 4:63,749,439...63,779,745
Ensembl chr 4:63,749,545...63,779,584
|
|
G |
Tnip2 |
TNFAIP3 interacting protein 2 |
decreases expression |
ISO |
Zinc Acetate results in decreased expression of TNIP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:34,653,440...34,671,323
Ensembl chr 5:34,653,431...34,671,335
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TRIB3 mRNA Zinc Acetate results in increased expression of TRIB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:152,179,345...152,185,980
Ensembl chr 2:152,179,342...152,185,952
|
|
G |
Trp53 |
transformation related protein 53 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein; Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] |
CTD |
PMID:20530418 |
|
NCBI chr11:69,471,174...69,482,699
Ensembl chr11:69,471,185...69,482,699
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TXNRD1 mRNA Zinc Acetate results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:82,669,785...82,733,558
Ensembl chr10:82,669,785...82,733,546
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
multiple interactions |
ISO |
[Taurine co-treated with Zinc Acetate] results in increased expression of UGT2B1 mRNA |
CTD |
PMID:26335259 |
|
NCBI chr 5:87,064,498...87,074,362
Ensembl chr 5:87,064,497...87,074,389
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of VEGFA mRNA Zinc Acetate results in increased expression of VEGFA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295
|
|
G |
Vhl |
von Hippel-Lindau tumor suppressor |
increases expression multiple interactions |
ISO |
Zinc Acetate results in increased expression of VHL mRNA motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of VHL mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 6:113,600,955...113,608,595
Ensembl chr 6:113,600,920...113,608,594
|
|